2024/08/16 12:51:40 | |
---|---|
Price | |
185.84 EUR | |
Difference | -2.38% (-4.54) |
ISIN | AU000000COH5 |
Symbol | COH |
Exchange | Tradegate |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 12,055 EUR |
Benchmark | ASX ALL ORDINARIES INDEX |
Bid (Bid size) | 185.00 EUR (38) |
Ask (Ask size) | 186.62 EUR (38) |
Open | 185.82 EUR |
High | 185.84 EUR |
Low | 185.82 EUR |
Close (prev. day) | 190.38 EUR |
VWAP | 185.824 EUR |
Volume (pcs) | 25 |
Trading volume | 4,645.60 |
Number of trades | 2 |
Last size | 5 |
Related Futures | - |
Related Options | 8 |
Date | Headline | Download | |
2024/08/12 |
![]() |
Global Equity Ratings |
![]() |
2024/07/24 |
![]() |
Global Equity Ratings |
![]() |
2024/07/12 |
![]() |
Global Equity Ratings |
![]() |
2024/06/21 |
![]() |
Global Equity Ratings |
![]() |
2024/06/14 |
![]() |
Global Equity Ratings |
![]() |
2024/08/16 12:51:40 | |
---|---|
Price | |
185.84 EUR | |
Difference | -2.38% (-4.54) |
ISIN | AU000000COH5 |
Symbol | COH |
Exchange | Tradegate |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 12,055 EUR |
Benchmark | ASX ALL ORDINARIES INDEX |
Bid (Bid size) | 185.00 EUR (38) |
Ask (Ask size) | 186.62 EUR (38) |
Open | 185.82 EUR |
High | 185.84 EUR |
Low | 185.82 EUR |
Close (prev. day) | 190.38 EUR |
VWAP | 185.824 EUR |
Volume (pcs) | 25 |
Trading volume | 4,645.60 |
Number of trades | 2 |
Last size | 5 |
6m | 1Y | 3Y | |
Perf (%) | -5.64% | +31.33% | +21.48% |
Perf (abs.) | -11.37 | +45.42 | +33.66 |
Beta | 0.94 | 0.88 | 0.89 |
Volatility | 25.30 | 24.24 | 28.10 |
Ø price 5 days | Ø volume 5 days (pcs.) | 201.66 EUR (44) |
Ø price 30 days | Ø volume 30 days (pcs.) | 202.87 EUR (42) |
Ø price 100 days | Ø volume 100 days (pcs.) | 199.81 EUR (41) |
Ø price 250 days | Ø volume 250 days (pcs.) | 183.49 EUR (45) |
YTD High | date | 209.95 EUR (2024/07/24) |
YTD Low | date | 170.52 EUR (2024/01/16) |
52 Weeks High | date | 209.95 EUR (2024/07/24) |
52 Weeks Low | date | 143.66 EUR (2023/10/26) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Tradegate | 2024/08/16 | 12:51 | 185.84 EUR | 0.00 | 2 |
Stuttgart | 2024/08/16 | 16:08 | 183.94 EUR | 0.02 | 3 |
Munich | 2024/08/16 | 08:00 | 184.42 EUR | 0.00 | 1 |
Hamburg | 2024/08/16 | 08:01 | 184.42 EUR | 0.00 | 1 |
Frankfurt | 2024/08/16 | 08:58 | 184.40 EUR | 0.00 | 1 |
FINRA other OTC Issues | 2024/08/14 | 18:23 | 235.10 USD | 0.02 | 1 |
Duesseldorf | 2024/08/16 | 19:30 | 184.24 EUR | 0.00 | 5 |
Berlin | 2024/08/16 | 08:08 | 184.44 EUR | 0.00 | 1 |
Australian Securities Exchange | 2024/08/16 | 08:10 | 305.56 AUD | 102.31 | 36,281 |
COCHLEAR LTD. |
- - |
14 Mars Road LANE - NSW 2066 COVE |
Telefon: (02) 9428 6555 |
Fax: (02) 9428 6354 |
E-mail: - |
- |
Dig Howitt | Chairman of Managing Board |
Brian Kaplan | Member of Executive Committee |
Anthony Bishop | Member of Executive Committee |
David Hackshall | Member of Executive Committee |
Dean Phizacklea | Member of Executive Committee |
Greg Bodkin | Member of Executive Committee |
Jan Janssen | Member of Executive Committee |
Jennifer Hornery | Member of Executive Committee |
Richard Brook | Member of Executive Committee |
Stuart Sayers | Member of Executive Committee |
Tony Manna | Member of Executive Committee |
Catriona Deans | Chairman of Supervisory Board |
Bruce Robinson | Member of Supervisory Board |
Michael Daniell | Member of Supervisory Board |
Christine McLoughlin | Member of Supervisory Board |
Glen Boreham | Member of Supervisory Board |
Karen Penrose | Member of Supervisory Board |
Michael del Prado | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer